These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22759596)

  • 1. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
    Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
    Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.
    Stiborová M; Moserová M; Černá V; Indra R; Dračínský M; Šulc M; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Frei E; Arlt VM
    Toxicology; 2014 Apr; 318():1-12. PubMed ID: 24530354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome b
    Reed L; Mrizova I; Barta F; Indra R; Moserova M; Kopka K; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Arch Toxicol; 2018 Apr; 92(4):1625-1638. PubMed ID: 29368147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
    Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
    Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of cytochrome P450 oxidoreductase enhances metabolism and DNA adduct formation of benzo[a]pyrene in Hepa1c1c7 cells.
    Reed L; Jarvis IWH; Phillips DH; Arlt VM
    Mutagenesis; 2019 Dec; 34(5-6):413-420. PubMed ID: 31612222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced DNA adduct formation by benzo[a]pyrene in human liver cells lacking cytochrome P450 oxidoreductase.
    Reed L; Jarvis IWH; Phillips DH; Arlt VM
    Mutat Res Genet Toxicol Environ Mutagen; 2020 Apr; 852():503162. PubMed ID: 32265041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice.
    Arlt VM; Singh R; Stiborová M; Gamboa da Costa G; Frei E; Evans JD; Farmer PB; Wolf CR; Henderson CJ; Phillips DH
    Drug Metab Dispos; 2011 Dec; 39(12):2169-73. PubMed ID: 21940903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
    Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detoxification of benzo[a]pyrene primarily depends on cytochrome P450, while bioactivation involves additional oxidoreductases including 5-lipoxygenase, cyclooxygenase, and aldo-keto reductase in the liver.
    Wang L; Xu W; Ma L; Zhang S; Zhang K; Ye P; Xing G; Zhang X; Cao Y; Xi J; Gu J; Luan Y
    J Biochem Mol Toxicol; 2017 Jul; 31(7):. PubMed ID: 28111842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat.
    Hodek P; Koblihová J; Kizek R; Frei E; Arlt VM; Stiborová M
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):989-96. PubMed ID: 24095716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
    Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice.
    Krais AM; Speksnijder EN; Melis JP; Indra R; Moserova M; Godschalk RW; van Schooten FJ; Seidel A; Kopka K; Schmeiser HH; Stiborova M; Phillips DH; Luijten M; Arlt VM
    Arch Toxicol; 2016 Apr; 90(4):839-51. PubMed ID: 25995008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzo[
    Dračínská H; Indra R; Jelínková S; Černá V; Arlt VM; Stiborová M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene.
    Fang C; Zhang QY
    J Pharmacol Exp Ther; 2010 Jul; 334(1):156-63. PubMed ID: 20400470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels.
    Uno S; Dalton TP; Shertzer HG; Genter MB; Warshawsky D; Talaska G; Nebert DW
    Biochem Biophys Res Commun; 2001 Dec; 289(5):1049-56. PubMed ID: 11741297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene.
    Stiborová M; Indra R; Moserová M; Frei E; Schmeiser HH; Kopka K; Phillips DH; Arlt VM
    Chem Res Toxicol; 2016 Aug; 29(8):1325-34. PubMed ID: 27404282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
    Henderson CJ; McLaughlin LA; Wolf CR
    Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.